Skip to main content

Table 5 Perioperative complications ≥grade II per the Clavien-Dindo classification

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

  SOX arm mFOLFOX6 arm Total
n=53 (%) n=48 (%) n=101 (%)
Postoperative hemorrhage
 IIIa 0 (0.0) 1 (2.1) 1 (1.0)
Intestinal anastomotic leakage
 II 1 (1.9) 1 (2.1) 2 (2.0)
 IIIa 1 (1.9) 0 (0.0) 1 (1.0)
 IIIb 4 (7.5) 0 (0.0) 4 (4.0)
Intra-abdominal abscess
 II 1 (1.9) 0 (0.0) 1 (1.0)
 IIIa 3 (5.7) 0 (0.0) 3 (3.0)
 IIIb 2 (3.8) 0 (0.0) 2 (2.0)
Wound infection
 II 4 (7.5) 1 (2.1) 5 (5.0)
IIIa 2 (3.8) 1 (2.1) 3 (3.0)
Ileus
 IIIa 1 (1.9) 2 (4.2) 3 (3.0)
 IIIb 1 (1.9) 2 (4.2) 3 (3.0)
Pneumonia
 II 0 (0.0) 1 (2.1) 1 (1.0)
  1. SOX: S-1 and oxaliplatin, mFOLFOX6: folinic acid, 5-FU, and oxaliplatin